



Encouraging Clinical Data on Visiogen's Synchrony® Dual Optic IOL presented at European Eye Care Conference
Strong Reception at Prestigious European Congress Bodes Well for Visiogen's Synchrony®

IRVINE, CA., October 18, 2006—Visiogen, Inc. of Irvine, California, was successfully received by attendees at the XXIV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in London from September 9 to 13. Four independent investigators presented their clinical results on Visiogen at the meeting, all with positive outcomes for the company's dual optic intraocular lens (IOL), Synchrony®.

Presentations included: "Reading Speed with Synchrony Dual optic Accommodating IOL," and "Accommodative Amplitude and Synchrony Dual optic IOL," by Victor Bohorquez, M.D.; "Functional Vision with Synchrony Dual optic Accommodating IOL," and "Innovation Technology. Synchrony preloaded Injector" by Ricardo Alarcon, M.D.; "Quality of Vision with the Synchrony Dual optic Accommodating IOL," and "Functional Vision with Synchrony Dual optic Accommodating IOL" by Ivan Ossma, M.D.; and "Visiogen Synchrony Dual optic Accommodating Lens; Initial Experience," by George H.H. Beiko, M.D., B.M., B. Ch., FRCSC. All showed positive results in initial use of the Synchrony IOL in cataract patients with a presbyopic condition.

"Our appearance at the ESCRS conference further corroborated our conviction that Synchrony® shows incredible promise for the correction of presbyopia after cataract surgery," said Luis G. Vargas, M.D., Medical Director at Visiogen. "Our investigators showed that visual outcomes using Synchrony are very good, and that the lens provides a complete and functional range of vision at all distances without compromising contrast sensitivity or induced photopic phenomena (i.e., glare, halos) that decrease quality of vision."

The Synchrony system incorporates a dual optic lens, with a proprietary easy-to-use pre-loaded injector. The entire system is self-contained and ready for use without the need for lens handling. The dual optic lens can be inserted through a 3.6 – 3.8 mm clear-corneal incision. The single-piece silicone lens unfolds in the eye upon insertion and features two optics connected by a spring system. The springs connect a 5.5-mm high power anterior optic and a 6-mm negative power posterior optic; the spring action moves the front optic and changes the eye's focus from near to far. This unique combination of positive- and negative-powered optics is customized for each patient.

Worldwide, the company has over 350 lenses implanted, and is currently conducting clinical trials for Synchrony in the United States. The company announced that it had received the European CE Mark for the Synchrony® Accommodating IOL in June which allows them to expand into post-marketing research studies within Europe to further build the scientific foundation for Synchrony.

###

About Visiogen

Visiogen, Inc. is focused on developing innovative products for cataract and refractive patients. Founded in Irvine, California, in 2001, Visiogen's first commercial application, Synchrony®, a dual optic intraocular lens and pre-loaded injector, is currently in clinical studies in the U.S. and recently received a CE Mark in Europe.

More information on the company and its offerings can be obtained by contacting:
Chuck Brauer or Kate Jennings
Maricich Communications for Visiogen, Inc.
Tel. 949-223-6455
Fax 949-223-6451
kate@maricich.com